Diurnal Group plc (DNL) Ordinary 5p

- Add to watchlist
- Create an alert
- This stock can be held in a




Share news, reports & tips
-
Director dealings: K3 director linked to purchase, Diurnal exec sells shares into ISA
9 May 2022 14:01
(Sharecast News) - Software company K3 Business Technology was at the top of the list of buys on Monday, after Kestrel Partners spent more than £40k on its shares.
-
Diurnal inks distribution agreement with Vector Pharma
30 March 2022 08:55
(Sharecast News) - Pharmaceutical company Diurnal has inked a distribution agreement with Vector Pharma for its Alkindi asset across the Middle East and North Africa.
-
Diurnal agrees special protocol with FDA for Chronocort study
12 July 2021 10:10
(Sharecast News) - Specialty pharmaceutical company Diurnal announced on Monday that the US Food and Drug Administration (FDA) has agreed a special protocol assessment (SPA) for 'Chronocort', or...
-
Diurnal gets UK approval for 'Efmody' treatment
2 July 2021 10:02
(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced on Friday that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted a marketing authorisation for...
-
Diurnal granted European patent for Alkindi
23 April 2021 10:31
(Sharecast News) - Hormonal disease-focussed speciality pharmaceutical company Diurnal Group announced the grant of a patent for 'Alkindi', or hydrocortisone granules in capsules for opening, by...
-
Alkindi sales drive revenue higher for Diurnal
23 February 2021 16:23
(Sharecast News) - Speciality pharmaceuticals company Diurnal reported 6% growth in first-half total revenue in its interim results on Tuesday, to £1.21m.
-
Diurnal enters Alkindi agreement for China region
27 January 2021 11:09
(Sharecast News) - Specialty pharmaceutical company Diurnal Group has entered into an exclusive licence agreement for its product 'Alkindi', or hydrocortisone granules in capsules for opening, with...
-
Diurnal gets European patent for 'Alkindi'
20 November 2020 12:04
(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced the grant of a patent for 'Alkindi', or hydrocortisone granules in capsules for opening, by the European Patent Office...
-
Diurnal up as its partner advances Swiss authorisation for 'Alkindi'
21 October 2020 15:40
(Sharecast News) - Speciality pharmaceuticals company Diurnal Group announced on Wednesday that its marketing and distribution partner in Switzerland, EffRx Pharmaceuticals, has submitted a market...
-
Diurnal raising up to £10m in placing and open offer
9 October 2020 16:13
(Sharecast News) - Speciality pharmaceuticals company Diurnal Group announced a proposed conditional placing with institutional investors to raise up to £8m before expenses on Friday, at a price of 60p per...
-
Diurnal signs two new distribution agreements in Europe
3 September 2020 11:35
(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced two further European market and distribution agreements for its products 'Alkindi', or hydrocortisone granules in...
-
Diurnal raises at least ?7m through conditional placing
6 March 2020 10:07
(Sharecast News) - Speciality pharmaceutical company Diurnal Group announced a conditional placing with institutional investors on Friday, to raise at least ?7m before expenses, at a price of 32p per new share.
Company announcements Announcements
-
Correction: Presentation at ECE
23 May 2022 08:41
Diurnal Group
-
Presentation at European Congress of Endocrinology
23 May 2022 07:00
Diurnal Group
-
Director Dealings
9 May 2022 12:49
Diurnal Group
-
Total Voting Rights
29 April 2022 15:37
Diurnal Group
-
Diurnal to present at Investor Evening
28 April 2022 07:00
Diurnal Group
-
Distribution agreement signed with EffRx
25 April 2022 07:00
Diurnal Group
-
Distribution agreement signed with Er-Kim
20 April 2022 07:00
Diurnal Group
-
Directorate Change and Management Updates
4 April 2022 07:00
Diurnal Group
-
Total Voting Rights
1 April 2022 07:00
Diurnal Group
-
Distribution agreement with Vector Pharma
30 March 2022 07:00
Diurnal Group
-
Price Monitoring Extension
22 March 2022 16:35
Diurnal Group
-
Second Price Monitoring Extn
22 March 2022 14:06
Diurnal Group
Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. This news service is operated by Digital Look Ltd. Republication or redistribution of Digital Look Ltd content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Digital Look Ltd. Please see https://www.sharecast.com/newsfeedterms/index.html for our terms and conditions.
© Digital Look Ltd 1998-2022. All rights reserved.

The London Stock Exchange does not disclose whether a trade is a buy or a sell so this data is estimated based on the trade price received and the LSE-quoted mid-price at the point the trade is placed. It should only be considered an indication and not a recommendation.
Trades priced above the mid-price at the time the trade is placed are labelled as a buy; those priced below the mid-price are sells; and those priced close to the mid-price or declared late are labelled 'N/A'.